Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent in differentiated thyroid cancer
NCT00668811Phase 2Completed
- Sponsor
- MedStar Health Research Institute
- Start
- Apr 2008
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in differentiated thyroid cancer (DTC), sponsored by MedStar Health Research Institute. Primary endpoint: Progression Free Survival. Started Apr 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT00668811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668811.